New England Journal of Medicine· 2017Q1
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
- 1,187citations
- Q1SCImago
- 2017year
Short summary
Adding temozolomide chemotherapy to short-course radiotherapy (40 Gy in 15 fractions) significantly increased median overall survival by 5.8 months (13.5 vs. 7.7 months) in elderly patients (≥65 years) with glioblastoma, particularly those with methylated MGMT status.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Genetics
GeneticsMedicine